Late Acute Cellular Rejection After Anakinra Treatment in a Kidney Transplant Patient, Is It a Coincidence?

Creative Commons License

Yeter H. H., Yetkin N., Akcay O. F., Derici Ü., Arinsoy T.

IRANIAN JOURNAL OF KIDNEY DISEASES, cilt.14, sa.4, ss.318-320, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 4
  • Basım Tarihi: 2020
  • Dergi Adı: IRANIAN JOURNAL OF KIDNEY DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.318-320
  • Gazi Üniversitesi Adresli: Evet

Özet

Familial mediterranean fever (FMF) is an autosomal recessive auto-inflammatory disorder, which could lead to secondary (AA) amyloidosis. Anakinra is an IL-1 receptor blocker and a treatment option for patients with FMF. There is no reported rejection episode associated with the use of Anakinra in the literature. A forty-nine years old woman with a history of kidney transplantation is described here. Anakinra was initiated in the patients whose FMF attacks were exacerbated, and the inflammation could not be controlled under the colchicine treatment. After eight months of follow up under Anakinra treatment, a moderate but persistent increase in serum creatinine level was observed. Allograft biopsy was compatible with acute T cell-mediated rejection with BANFF type 2A. Data on the use of Anakinra in KTRs is limited. Antidrug-antibodies or hapten induced T cell activation may facilitate late-onset acute T cell-mediated rejection in the patient who used Anakinra.